Financials in USD. Standardized financial statements.
A compact view of how Channel Therapeutics Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $16.80M | $0 | $0 | $0 | $0 | $199,934 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $2.58M | $391,730 | $209,047 | $138,585 |
| Gross Profit? | $0 | $0 | -$2.58M | -$391,730 | -$209,047 | $61,349 |
| Gross Margin? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +30.7% |
| Operating Expenses? | $49.23M | $7.57M | $6.86M | $2.32M | $838,996 | $1.55M |
| Operating Income? | $0 | -$7.57M | -$6.86M | -$2.32M | -$839,000 | -$1.35M |
| EBITDA? | $0 | -$7.57M | -$6.86M | -$1.63M | $0 | $0 |
| Income Before Tax | -$50.71M | -$7.96M | -$7.38M | -$2.46M | -$595,387 | -$660,584 |
| Income Tax Expense | -$7.39M | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$43.32M | -$7.96M | -$7.38M | -$2.46M | -$595,387 | -$660,584 |
| EPS? | $-23.04 | $-1.43 | $-1.28 | $-0.43 | $-0.10 | $-0.11 |
| Diluted EPS? | $-23.04 | $-1.43 | $-1.28 | $-0.43 | $-0.10 | $-0.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality